Related by context. All words. (Click for frequent words.) 79 non inferiority 73 noninferior 70 prospectively defined 70 achieved statistical significance 70 active comparator 70 efficacy endpoint 69 nonrandomized 69 multicentre randomized 69 prespecified 68 statistical significance 68 randomized multicenter 68 eplerenone 67 mRCC 67 tecarfarin 67 pharmacokinetics PK 67 statistical significance p 66 RE LY ® 66 placebo controlled clinical 66 RE LY 66 unfractionated heparin 66 prospective randomized controlled 66 viral kinetics 66 abacavir lamivudine 66 virologic response 66 posaconazole 66 DAPT 66 secondary efficacy endpoints 65 tocilizumab 65 primary endpoint 65 subgroup analyzes 65 statistically significant p = 65 Kaplan Meier analysis 65 desvenlafaxine succinate 65 pharmacokinetic PK 65 phase IIIb 65 randomized multicenter trial 65 genotypic resistance 65 primary efficacy endpoint 65 platelet inhibitor 65 virologic failure 65 efficacy endpoints 65 eptifibatide 65 PREZISTA r 65 analgesic efficacy 65 Doxil ® 65 viral kinetic 65 pharmacodynamics PD 65 composite endpoint 65 pharmacokinetic equivalence 65 abciximab 65 surrogate endpoint 65 chlorambucil 65 doxorubicin docetaxel 65 Non inferiority 65 mCRC patients 64 XIENCE V PROMUS Stent 64 ticagrelor 64 dose escalation 64 pharmacodynamic properties 64 morphometric vertebral fractures 64 mcg dose 64 prospective multicenter randomized 64 temsirolimus 64 tapentadol ER 64 peginterferon alfa 2b 64 PRIMO CABG 64 fondaparinux 64 bosentan 64 maximally tolerated dose 64 everolimus eluting stents 64 intravenous dosing 64 oral anticoagulation 64 multicenter randomized placebo controlled 64 sirolimus eluting stents 64 HBeAg seroconversion 64 undetectable HBV DNA 64 lopinavir r 64 binary restenosis 64 TRITON TIMI 64 prospective multicenter 64 nab paclitaxel 64 mg kg dose 64 ROCKET AF 64 mg/m2 dose 64 secondary efficacy endpoint 64 tanespimycin 64 SVR# 64 mITT population 64 sunitinib 64 randomized blinded 63 placebo controlled trials 63 zotarolimus eluting stent 63 CCyR 63 rt PA 63 pegylated interferon alfa 2b 63 dabigatran etexilate 63 antipsychotic efficacy 63 serum phosphorus 63 FOLPI 63 bivalirudin 63 sirolimus eluting stent 63 ExTRACT TIMI 63 EURIDIS 63 seroprotection 63 randomized Phase III 63 multicenter randomized 63 oral rivaroxaban 63 sustained virological response 63 sirolimus stent 63 LEXIVA r 63 apremilast 63 IOP lowering 63 teriflunomide 63 primary efficacy endpoints 63 GORE VIABAHN Endoprosthesis 63 CR nPR 63 double blinded randomized 63 valvulopathy 63 EDEMA3 63 iniparib 63 sorafenib Nexavar 63 cangrelor 63 pharmacodynamic PD 63 prespecified criteria 63 NATRECOR ® 63 tirofiban 63 clinical endpoints 63 abatacept 63 irbesartan 63 cilostazol 63 dalteparin 63 FOLFOX4 63 rolofylline 63 multicenter randomized controlled 63 dosage regimens 63 oral ridaforolimus 63 LPV r 63 TMC# C# 63 Phase Ib study 63 complete cytogenetic response 63 everolimus eluting stent 63 Primary endpoints 63 GAMMAGARD 63 pertuzumab 63 nonresponders 63 ribavirin RBV 63 secondary endpoint 63 idraparinux 63 ABC/3TC 63 comparator arm 63 BENICAR HCT 63 mg QD 63 bendamustine 63 darunavir ritonavir 63 randomized multicentre 63 attain statistical significance 62 ritonavir boosted 62 peg interferon 62 AVERROES 62 FOLFIRI 62 QTc 62 Randomized controlled 62 virologic 62 mg dose 62 MabCampath 62 protease inhibitor PI 62 liposomal amphotericin B 62 achieve statistical significance 62 5-FU/LV 62 micafungin 62 periprocedural MI 62 definite stent thrombosis 62 pCR 62 titrated glipizide 62 Omacetaxine mepesuccinate 62 HCV SPRINT 62 STRIDE PD 62 invasive aspergillosis 62 pain palliation 62 PegIFN 62 ritonavir boosted lopinavir 62 dose clopidogrel 62 PEG IFN 62 TAXUS Express Stent 62 plus dexamethasone 62 tipranavir 62 ATACAND 62 tolvaptan 62 NEVO ™ 62 dose regimens 62 ancrod 62 gadobutrol 62 riociguat 62 unfractionated heparin UFH 62 lumbar spine BMD 62 Ceplene/IL-2 62 boosted protease inhibitor 62 paroxysmal AF 62 GP IIb IIIa inhibitors 62 pharmacokinetic PK study 62 phase Ib 62 cisplatin vinorelbine 62 Pharmacokinetic studies 62 pharmacodynamic 62 ULORIC 62 MAGE A3 ASCI 62 CANCIDAS 62 VELCADE melphalan 62 azacitidine 62 mycophenolate mofetil 62 ARB telmisartan 62 HBeAg negative patients 62 NATRECOR R 62 peginterferon 62 prospective randomized multicenter 62 adenoma recurrence 62 fluvastatin 61 tacrolimus ointment 61 RAPAFLO R 61 EORTC 61 HCV RESPOND 2 61 somatostatin analog 61 multivariate Cox 61 periprocedural 61 tolerated dose MTD 61 carotid artery stenting 61 ertapenem 61 TAXUS VI 61 pharmacokinetic parameters 61 null hypothesis 61 thromboembolic events 61 amoxicillin clavulanate 61 phase IIb clinical 61 Cmax 61 FDA defined valvulopathy 61 optimal dosing 61 biochemical recurrence 61 adalimumab 61 peginterferon alfa 2a 61 prucalopride 61 β blockers 61 HbA 1c 61 carboplatin paclitaxel 61 neurologic progression 61 randomized controlled clinical 61 virological response 61 ARCOXIA 61 platelet reactivity 61 sipuleucel T 61 Capesaris 61 HORIZONS AMI trial 61 neoadjuvant chemotherapy 61 corrected QT interval 61 efficacy 61 ACCORD Lipid 61 virological failure 61 Cytoxan 61 DAS# remission 61 CYPHER ® Stent 61 endoscopic remission 61 iloprost 61 XIENCE V demonstrated 61 pharmacokinetic characteristics 61 DLTs 61 Tarceva TM 61 plus prednisone 61 ONTARGET 61 clinically meaningful differences 61 imatinib therapy 61 trabectedin 61 bioequivalency 61 TAXUS V 61 plus ribavirin 61 serum phosphorous 61 carotid stenting 61 subcutaneously administered 61 anti leukemic 61 subanalysis 61 Randomized clinical trials 61 pegylated interferon alfa 61 ZOLINZA 61 CIMZIA TM 61 dacarbazine 61 Cypher Stent 61 dexpramipexole 61 certolizumab 61 TAXUS Stent 61 tolerability 61 efavirenz EFV 61 PFO migraine 61 recurrent glioblastoma multiforme 61 mcg kg 61 EchoCRT 61 Randomised 61 trials RCTs 61 pharmacokinetic profiles 61 Subgroup analysis 61 GOUT 61 Thrombolysis 61 randomized controlled 61 melphalan prednisone 61 prespecified secondary 61 decitabine 61 multicenter placebo controlled 61 cinacalcet 61 #mg QD [002] 61 dose escalation trial 61 chemotherapy docetaxel 61 eszopiclone 61 NSTE ACS 61 primary endpoints 61 alvimopan 61 postmenopausal osteoporotic women 61 IV bisphosphonates 61 ximelagatran 61 univariate 61 TAXUS stent 61 trastuzumab Herceptin ® 61 ENDEAVOR IV 61 Perforomist Inhalation Solution 61 levosimendan 61 KRAS mutations occur 61 Taxus Stent 61 velafermin 61 caspofungin 61 nicardipine 61 lispro 60 CsA 60 intravesical therapy 60 galiximab 60 fluoropyrimidine 60 linezolid 60 oral diclofenac 60 intraobserver 60 liposomal doxorubicin 60 sustained virologic response 60 multicentre 60 nucleoside naive patients 60 elotuzumab 60 ranolazine 60 lanthanum carbonate 60 Traficet EN 60 gefitinib 60 ADAS cog 60 ACTEMRA TM 60 delafloxacin 60 ACUITY trial 60 statistically significant efficacy 60 Phase 2a trial 60 methotrexate monotherapy 60 dose escalation clinical 60 dose proportionality 60 therapeutic equivalence 60 retrospective observational study 60 MIRCERA 60 pharmacodynamic effects 60 mg/m2 cohort 60 achieved ACR# 60 oral Xeloda 60 Targretin 60 phase IIa 60 baminercept 60 oxycodone CR 60 CALGB # [002] 60 pegylated liposomal doxorubicin 60 antiplatelet agent 60 BENICAR 60 placebo controlled studies 60 metastatic HRPC 60 Torisel 60 telmisartan 60 GFT# 60 Aflibercept 60 rFVIIa 60 antiangiogenic agent 60 postintervention 60 randomized clinical 60 doripenem 60 phase IIb study 60 elevated troponin 60 confirmatory clinical 60 clevidipine 60 lamivudine refractory patients 60 fluticasone salmeterol 60 TACE 60 revascularizations 60 dose cohort 60 dosing cohort 60 QT QTc 60 CHAMPION PLATFORM 60 ischemic cardiomyopathy 60 double blinded placebo 60 liposomal formulation 60 plasma pharmacokinetics 60 μg dose 60 LMWH 60 octreotide LAR 60 Response Evaluation Criteria 60 median PFS 60 PTNS 60 phase IIb 60 bioequivalence 60 fosbretabulin 60 chemoradiotherapy 60 PIX# [002] 60 ILLUMINATE 60 tiotropium 60 #mg BID [001] 60 Stenting Trial CREST 60 tigecycline 60 biologic therapy 60 Myocardial Infarction Study 60 crizotinib PF # 60 GP IIb IIIa inhibitor 60 ibandronate 60 tipranavir r 60 prospective randomized 60 favorable pharmacokinetic profile 60 CIMZIA TM certolizumab pegol 60 hemoglobin A1c levels 60 ABVD 60 KRAS status 60 piperacillin tazobactam 60 paclitaxel eluting stents 60 ug kg 60 ORMD 60 COMBIVIR 60 μmol L 60 efficacy tolerability 60 Ereska 60 imipenem 60 leukocyte count 60 clinically meaningful 60 rALLy trial 60 antihypertensive therapy 60 axitinib 60 ADAS Cog 60 oral vancomycin 60 EGFR TKI 60 gemcitabine carboplatin 60 VADT 60 MERLIN TIMI 60 AEGR 60 Carotid Revascularization Endarterectomy vs. 60 nilotinib 60 label multicenter 60 limiting toxicity 60 creatinine clearance 60 CYPHER Stent 60 IIIa inhibitor 60 mapatumumab 60 Secondary efficacy endpoints 60 INVEGA ® 60 goserelin 60 blinded randomized 60 efficacy evaluable 60 Darusentan 60 ezetimibe simvastatin 60 post hoc 60 liver histology 60 procalcitonin 60 pegylated interferon alpha 60 phase IIa clinical 60 antiarrhythmic drug 60 thorough QT 60 plus COPEGUS 60 clinically meaningful improvement 60 T#I [002] 60 Study GL# 60 iclaprim 60 valsartan 60 adefovir treated 60 metastatic renal cell carcinoma 60 ruboxistaurin 59 Pemetrexed 59 carotid endarterectomy CEA 59 relapsed MM 59 IFN α 59 XELOX 59 AZOR 59 Ranolazine 59 LCP Tacro ™ 59 intravesical 59 ABSORB trial 59 Phase 2b study 59 dasatinib 59 pharmacokinetic pharmacodynamic 59 vandetanib 59 ALLHAT 59 endarterectomy 59 dexmedetomidine 59 DAS# CRP 59 pg mL 59 urinary N telopeptide 59 Dabigatran 59 timolol 59 CIMZIA ™ 59 dronedarone 59 TPV r 59 #mg QD [001] 59 thienopyridine 59 recurrent GBM 59 Phase #/#a 59 tipranavir ritonavir 59 antitumor activity 59 icatibant 59 SCH # 59 reslizumab 59 neoadjuvant 59 Pharmacokinetic 59 IRESSA 59 nonoperative 59 elective PCI 59 ziprasidone 59 paclitaxel carboplatin 59 Amrubicin 59 RoACTEMRA 59 dosing regimens 59 mg qd 59 glatiramer acetate 59 conditional logistic regression 59 DES implantation 59 CYPHER ® Sirolimus eluting 59 atazanavir ritonavir 59 PD LID 59 FOLFOX 59 MMSE score 59 assessing T DM1 59 rEEG 59 ARIXTRA 59 empiric 59 inhibitor RG# 59 vicriviroc 59 nondiabetic patients 59 colorectal liver metastases 59 monotherapy 59 darunavir 59 OvaRex MAb 59 adefovir 59 pharmacokinetic profile 59 BRIM3 59 multicenter clinical 59 reach statistical significance 59 CTEPH 59 CoFactor 59 DU #b 59 regorafenib 59 PRT# 59 insulin detemir 59 multicenter randomized double 59 IFN beta 59 ACR# response 59 HbA1c levels 59 methacholine challenge 59 progression TTP 59 placebo controlled randomized 59 alteplase 59 evaluating tivozanib 59 leukemia CLL 59 TLUS 59 Platinol 59 investigational antiplatelet agent 59 HES CEL 59 ANCHOR trial 59 Subgroup analyzes 59 locoregional recurrence 59 Betaferon ® 59 mg BID dose 59 rosuvastatin 59 sitaxsentan 59 mcg mL 59 CHAMPION PCI 59 RSR# efaproxiral 59 BRIM2 59 atorvastatin #mg 59 intermittent dosing 59 CLORETAZINE TM VNP#M 59 mitomycin 59 elagolix 59 KRN# 59 NYHA functional class 59 Phase #b/#a trial 59 heavily pretreated 59 Randomized Evaluation 59 preoperative chemotherapy 59 colesevelam HCl 59 CRp 59 maximal tolerated 59 A1c levels 59 CI -#.# 59 QTc prolongation 59 Peg IFN 59 prospectively stratified 59 olmesartan 59 dose regimen 59 angiographic outcomes 59 LB# [003] 59 APTIVUS r 59 rizatriptan 59 Solid Tumors criteria 59 p = .# [002] 59 bevacizumab Avastin ® 59 TELCYTA 59 thromboprophylaxis 59 leflunomide 59 vidofludimus 59 diameter stenosis 59 interobserver reliability 59 % CI #.#-#.# [003] 59 pretest probability 59 pramlintide metreleptin combination 59 divalproex sodium 59 prospective randomized placebo 59 mg BID 59 placebo controlled clinical trials 59 multicenter multinational 59 unblinded 59 sUA 59 TAXUS Liberte Long 59 adecatumumab 59 aleglitazar 59 rilpivirine 59 edoxaban 59 Pharmacokinetic parameters 59 TRANSFORMS 59 xanthine oxidase inhibitor 59 antiangiogenic therapy 59 budesonide 59 dose escalation Phase 59 aldosterone antagonists 59 ganetespib 59 fibrinolytic therapy 59 Ziprasidone 59 APTIVUS 59 microdose 59 eluting stent 59 retapamulin 59 pharmacodynamic endpoints 59 reinfarction 59 placebo p = 59 fulvestrant 59 antiviral efficacy 59 TAXUS IV 59 aldosterone antagonist 59 pomalidomide 59 inhaled iloprost 59 deferiprone 59 atherothrombotic events 59 Pegasys ® 59 SIMPADICO 59 UKPDS 59 sirolimus eluting 59 logistic regression models 59 secondary endpoints 59 octreotide 59 vinorelbine 59 administered subcutaneously 59 lipid lowering therapy 59 MoxDuo TM IR 59 adjunctive placebo 59 F FDG PET 59 FFNS 59 Ophena TM 59 PEG interferon 59 trastuzumab emtansine T DM1 59 EDEMA3 trial 59 candesartan cilexetil 59 LVEF 59 CYPHER R Sirolimus eluting 59 edifoligide 59 Montgomery Åsberg Depression 59 prospectively randomized 59 % Confidence Interval 59 RECIST Response Evaluation Criteria 59 nesiritide 59 ustekinumab 59 HbA 1c levels 59 PEGINTRON TM 59 antithrombotic therapy 59 pharmacokinetic PK profile 59 Durezol 59 symptomatic VTE 59 NSABP B 59 ongoing Phase 1b 59 interferon gamma 1b 59 interferon alfa 2b 59 osteopenic 59 dosage regimen 58 undetectable HCV RNA 58 posttreatment 58 glycated hemoglobin levels 58 relapsed SCLC 58 antithrombotic 58 CINQUIL 58 Engerix B 58 #mg dose [003] 58 stage IIIB 58 Secondary endpoints 58 RTOG 58 clomipramine 58 ToGA 58 ACCOMPLISH 58 NLX P# 58 endoscopic gastric ulcers 58 plasma uric acid 58 cariprazine 58 antibody titer 58 unstable angina UA 58 pegylated interferons 58 bi ventricular pacing 58 #.#/#.# mmHg [001] 58 asymptomatic metastatic 58 p ≤ 58 MGd 58 rivaroxaban 58 fosamprenavir 58 mTOR inhibitor 58 salmeterol fluticasone 58 ACTIVE W 58 EOquin TM 58 NCEP ATP III 58 blinded randomized placebo controlled 58 anthracycline containing 58 Dabigatran etexilate 58 FOLFOX6 58 latanoprost 58 docetaxel chemotherapy 58 oral FTY# 58 venlafaxine XR 58 ASTEROID 58 Dose escalation 58 antitumor effect 58 TAXUS Liberte Stent 58 Fludara 58 concurrent chemoradiation 58 imatinib resistant 58 relapsed refractory multiple myeloma 58 ritonavir boosting 58 locoregional disease 58 Bezielle 58 Corlux 58 VAPRISOL 58 PERSEUS 58 antiretroviral naïve 58 NovoTTF 58 imetelstat 58 Teriflunomide 58 fluorouracil 58 infliximab 58 Elitek 58 Instanyl 58 substudy 58 zalutumumab 58 randomisation 58 lintuzumab 58 tenofovir emtricitabine 58 azilsartan medoxomil 58 Hb A1C 58 favorable tolerability 58 mitoxantrone 58 cobicistat 58 recurrent VTE 58 entecavir 58 placebo controlled 58 radiographic progression 58 TNSS 58 bicifadine 58 COPAXONE R 58 Ambrisentan 58 Vectibix monotherapy 58 RE LY trial 58 standard chemotherapy regimen 58 #mg BID [003] 58 mCi kg 58 pimecrolimus cream 58 orBec 58 HBeAg positive patients 58 virological suppression 58 Pred Forte 58 SCIg 58 L PPDS 58 APPRAISE 58 clodronate 58 AST ALT 58 XGEVA 58 intravenously administered 58 LUX Lung 58 daunorubicin 58 trastuzumab 58 NRTI 58 peginterferon alfa 2a #KD 58 chlorthalidone 58 XIENCE V Everolimus Eluting 58 CR CRu 58 RezularTM 58 Kaplan Meier curves 58 dose atorvastatin 58 tolerability profiles 58 mcg BID 58 #mg/day [001] 58 metastatic RCC 58 HbA1C 58 interferon ribavirin 58 anagrelide 58 brivaracetam 58 etanercept 58 ketorolac 58 INCB# [003] 58 febuxostat 58 Navelbine 58 nelfinavir 58 ASCEND HF 58 CLL8 58 dose Iluvien 58 refractory AML 58 EVEREST II 58 dosing regimen 58 percutaneous intervention 58 Tolvaptan 58 hsCRP levels 58 glargine 58 lymphadenectomy 58 Dasatinib 58 clazosentan 58 carotid IMT 58 erlotinib Tarceva ® 58 Aclidinium 58 paricalcitol 58 QD dosing 58 dose escalation phase 58 reteplase 58 relapsing multiple sclerosis 58 AVADO 58 enoxaparin 58 Phase III randomized 58 DDP# 58 controlled multicenter 58 non squamous histology 58 carotid artery stenting CAS 58 P = .# 58 reboxetine 58 mg p = 58 blind placebo 58 lipid lowering drugs 58 CRESTOR #mg 58 Maximum Tolerated Dose MTD 58 antimicrobial prophylaxis 58 remission induction 58 logistic regression analysis 58 alvespimycin 58 HyQ 58 hemostatic efficacy 58 Lenalidomide 58 landmark ATHENA 58 ZD# [001] 58 risedronate 58 randomized controlled Phase 58 adjuvant therapy 58 confidence interval CI 58 PSA nadir 58 anticoagulation 58 rapid virologic response 58 trastuzumab DM1 58 ribavirin therapy 58 randomized clinical trials 58 direct thrombin inhibitors 58 ascending dose 58 enoximone 58 PRECISE 58 #.#mg/dL 58 sunitinib malate 58 thienopyridines 58 mg doses 58 RRMS patients 58 antiarrhythmic 58 Aplidin 58 Octreolin 58 pamidronate 58 docetaxel pretreated 58 μg kg 58 blinded placebo controlled 58 Phase IIa clinical 58 GRAVITAS trial 58 Solid Tumors RECIST 58 satraplatin Phase 58 stable angina 58 Combination therapy 58 amlodipine 58 PRECiSE 58 eribulin mesylate 58 angiotensin receptor blocker ARB 58 platelet inhibition 58 CBLC# 58 #mg dose [002] 58 EGFR TKIs 58 NV1FGF 58 platinum refractory 58 afatinib 58 palonosetron 58 multicentre randomized double 58 curative resection 58 plasma kallikrein inhibitor 58 tamsulosin 58 ramipril 58 mg TID 58 TNF alpha inhibitor 58 NEVO TM 58 metformin monotherapy 58 unblinding 58 sorafenib 58 stage IIIb IV 58 cediranib 58 sorafenib Nexavar ® 58 EBRT 58 Fidaxomicin 58 candesartan 58 superficial bladder cancer 58 relapsed refractory 58 TORISEL 58 daily Infergen 58 undetectable viral load 58 tenecteplase 58 ACR# [002] 58 microbiologically evaluable 58 dose limiting toxicities 58 postoperative chemotherapy 58 preclinically 58 neratinib 58 BARACLUDE ® 58 HuMax EGFr 58 transdermal estradiol 58 prostate carcinoma 58 p = NS 58 TYGACIL 57 tolevamer 57 INCB# [002] 57 alpha 2a 57 interferon alfa 57 evaluable subjects 57 factor Xa inhibitor 57 AIM HIGH 57 response CCyR 57 MitraClip device 57 voriconazole 57 Bioequivalence 57 evaluable 57 HER2 expression 57 PegIntron 57 CorVue ™ 57 MADIT 57 REYATAZ r 57 BAY #-# 57 non squamous NSCLC 57 strontium ranelate 57 Allovectin 7 ® 57 Flu Cy 57 CALGB 57 Hazard Ratio 57 Resolute DES 57 immunohistochemical 57 aliskiren 57 resectable 57 immunomodulatory therapy 57 Percutaneous Coronary Intervention 57 REMINYL ® 57 timepoints 57 p = #.# [003] 57 mildly symptomatic 57 bortezomib 57 SPIRIT FIRST 57 probable stent thrombosis 57 enfuvirtide 57 biphasic insulin aspart 57 subcutaneous insulin 57 pharmacokinetic interaction 57 locoregional 57 triple nucleoside 57 preoperative PSA 57 mITT 57 masked placebo controlled 57 darunavir r 57 MoxDuo ® IR 57 pentoxifylline 57 cetuximab Erbitux R 57 mesalamine granules 57 Ophena 57 % CI #.#-#.# [007] 57 Panzem R NCD 57 CA9 SCAN 57 nonsignificant 57 univariate analysis 57 GIK infusion 57 drotrecogin alfa activated 57 oral allopurinol 57 safety tolerability pharmacokinetic 57 sotalol 57 zoledronic acid 57 Virulizin ® 57 EFAPROXYN